Tuesday, June 6, 2023
Home Psychedelic Stock Review 2023 Watch List

2023 Watch List

    Most popular
    Silo Pharma, Psychedelic Stock Review, Roland Rick Perry

    SILO Pharma (SILO) Gains 53%

    2023 Watch List Editor / Curator -
    For Now, Volatility Remains and the Traders, Seem to be Having the Most Fun. Silo Pharma Gains 53%...

    Silo Pharma (SILO) $2.25, Now Our Favorite Psychedelic.

    Biotech News Editor / Curator -
    We Liked it at $3.50, we Love it at $2.25. Down but not out. Now trading below the...

    The Ketamine Endgame. Silo Pharmaceutical (SILO).

    Psychedelic Stock Review Editor / Curator -
    James Kuo, M.D. the Vice President of R&D for Silo Pharma (SILO) will speak at the 3rd...
    Zappy Zapolin, Lamar Odom, Roland Rick Perry

    Adding Psycheceutical Bioscience (BWVI) $0.14 to Watch List. Ketamine.

    2023 Watch List Editor / Curator -
    Above: Lamar Odom and Psychedelic Spokesman Mike Zappy Zapolin We're Calling a Sector Bottom, and Psycheceutical (BWVI) as Our...

    Latest article

    Asia-Pacific: A Region of Stability Amidst Economic Uncertainty

    2022 Watch List Editor / Curator -
    Contrary to the Western markets, there is a growing consensus that the Asia Pacific is emerging as a relatively safe harbour in...

    Hepion (HEPA) Back in the Spotlight, Gains 230% in May.

    2020 Watch List Editor / Curator -
    Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...

    Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating...

    2023 Watch List Editor / Curator -
    A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of...
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: roland@institutionalanalyst.com
    © Managed by Revelers.IO Media Group Inc.